Raymond James analyst Brian Gesuale initiated coverage on the stock with a strong buy rating and a Street-high price target ...
Working during retirement could be a great decision for both your finances and your general well-being. A part-time job can ...
Any of these blue chip stocks would be solid long-term picks. One of them, however, is especially underestimated right now.
According to data from S&P Global Market Intelligence, the stock lost 17% last month. As you can see from the chart below, ...
Vertex Pharmaceuticals (VRTX 1.39%) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics ...
There are a few things about the First Trust Nasdaq Semiconductor ETF that set it apart from most of its competitors and make ...
Meta Platforms (META +2.59%) could spend as much as $145 billion on AI in 2026 alone. That is a staggering amount of money, and Wall Street has grown increasingly nervous that the ...
So, while SpaceX is still deeply unprofitable and probably will be for some time, investors expect strong profits down the ...
In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (VRTX 1.31%) and Crinetics Pharmaceuticals (CRNX +98.74%) announced in a joint press release t ...
SpaceX reached a multi-year deal with Alphabet that will average to $920 million per month, starting in October. SpaceX w ...
Its acquisition of Cursor demonstrates that it recognizes the importance of creating a robust AI platform -- but it also ...
Micron stock has soared about 242% in 2026 as of this writing, and it crossed $1 trillion in market value along the way. A run like that doesn't happen unless the market is already counting on blowout ...